229 related articles for article (PubMed ID: 22286341)
21. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
22. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
[TBL] [Abstract][Full Text] [Related]
23. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
Willmon CL; Saloura V; Fridlender ZG; Wongthida P; Diaz RM; Thompson J; Kottke T; Federspiel M; Barber G; Albelda SM; Vile RG
Cancer Res; 2009 Oct; 69(19):7713-20. PubMed ID: 19773437
[TBL] [Abstract][Full Text] [Related]
24. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
25. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
[TBL] [Abstract][Full Text] [Related]
26. Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.
Guayasamin RC; Reynolds TD; Wei X; Fujiwara M; Robek MD
J Virol; 2014 Sep; 88(18):10909-17. PubMed ID: 25008938
[TBL] [Abstract][Full Text] [Related]
27. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.
Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):150-8. PubMed ID: 20959810
[TBL] [Abstract][Full Text] [Related]
28. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
30. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D
Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868
[TBL] [Abstract][Full Text] [Related]
31. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.
van den Pol AN; Mao G; Chattopadhyay A; Rose JK; Davis JN
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077641
[TBL] [Abstract][Full Text] [Related]
32. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
33. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
[TBL] [Abstract][Full Text] [Related]
35. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
Majid AM; Ezelle H; Shah S; Barber GN
J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305
[TBL] [Abstract][Full Text] [Related]
36. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
Obuchi M; Fernandez M; Barber GN
J Virol; 2003 Aug; 77(16):8843-56. PubMed ID: 12885903
[TBL] [Abstract][Full Text] [Related]
37. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
38. [Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].
Hadaschik BA; Zhang K; So AI; Bell JC; Thüroff JW; Rennie PS; Gleave ME
Urologe A; 2008 Sep; 47(9):1145-51. PubMed ID: 18670747
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL
J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290
[TBL] [Abstract][Full Text] [Related]
40. Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
Capo-chichi CD; Yeasky TM; Heiber JF; Wang Y; Barber GN; Xu XX
Gynecol Oncol; 2010 Feb; 116(2):269-75. PubMed ID: 19932656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
